Targeted alpha anticancer therapies: update and future prospects

Targeted alpha therapy (TAT) is an emerging option for local and systemic cancer treatment. Preclinical research and clinical trials show that alpha-emitting radionuclides can kill targeted cancer cells while sparing normal cells, thus reducing toxicity. 223RaCl2 (Xofigo®) is the first alpha emitting radioisotope to gain registration in the US for palliative therapy of prostate cancer bone metastases by indirect physiological targeting. The alpha emitting radioisotopes 211At, 213Bi, 225Ac and 227Th are being used to label targeting vectors such as monoclonal antibodies for specific cancer therapy indications. In this review, safety and tolerance aspects are considered with respect to microdosimetry, specific energy, Monte Carlo model calculations, biodosimetry, equivalent dose and mutagenesis. The clinical efficacy of TAT for solid tumors may also be enhanced by its capacity for tumor anti-vascular (TAVAT) effects. This review emphasizes key aspects of TAT research with respect to the PAI2-uPAR complex and the monoclonal antibodies bevacizumab, C595 and J591. Clinical trial outcomes are reviewed for neuroendocrine tumors, leukemia, glioma, melanoma, non-Hodgkins lymphoma, and prostate bone metastases. Recommendations and future directions are proposed.

[1]  S. Fosså,et al.  First Clinical Experience with α-Emitting Radium-223 in the Treatment of Skeletal Metastases , 2005, Clinical Cancer Research.

[2]  S. Larson,et al.  Sequential Cytarabine and α-Particle Immunotherapy with Bismuth-213–Lintuzumab (HuM195) for Acute Myeloid Leukemia , 2010, Clinical Cancer Research.

[3]  J. Staffurth,et al.  A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. , 2012, European journal of cancer.

[4]  N. Bander,et al.  In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen , 2002, Prostate Cancer and Prostatic Diseases.

[5]  J. Little,et al.  The radiation-induced bystander effect: evidence and significance , 2004, Human & experimental toxicology.

[6]  D. Wilbur.  Chemical and radiochemical considerations in radiolabeling with α-emitting radionuclides. , 2011, Current radiopharmaceuticals.

[7]  S. Fosså,et al.  First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  B. Allen,et al.  Targeted Alpha Therapy Approach to the Management of Pancreatic Cancer , 2011, Cancers.

[9]  B. Allen,et al.  Analysis of patient survival in a Phase I trial of systemic targeted α-therapy for metastatic melanoma. , 2011, Immunotherapy.

[10]  S. Larson,et al.  Bone-Seeking Radiopharmaceuticals for Treatment of Osseous Metastases, Part 1: α Therapy with 223Ra-Dichloride , 2014, The Journal of Nuclear Medicine.

[11]  Yong Li,et al.  Cytotoxicity of human prostate cancer cell lines in vitro and induction of apoptosis using 213Bi-Herceptin alpha-conjugate. , 2004, Cancer letters.

[12]  Yong Li,et al.  Pre-clinical Study of 213Bi Labeled PAI2 for the Control of Micrometastatic Pancreatic Cancer , 2005, Clinical & Experimental Metastasis.

[13]  A. Merlo,et al.  Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[14]  J. Reubi,et al.  Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN). , 2011, Cancer research.

[15]  R. Senekowitsch-Schmidtke,et al.  177Lu-immunotherapy of experimental peritoneal carcinomatosis shows comparable effectiveness to 213Bi-immunotherapy, but causes toxicity not observed with 213Bi , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[16]  I Syndikus,et al.  Alpha emitter radium-223 and survival in metastatic prostate cancer. , 2013, The New England journal of medicine.

[17]  B. J. Allen.  Can alpha-immunotherapy succeed where other systemic modalities have failed? , 1999, Nuclear medicine communications.

[18]  J. Nesland,et al.  Assessment of long-term radiotoxicity after treatment with the low-dose-rate alpha-particle-emitting radioimmunoconjugate 227Th-rituximab , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[19]  D. Scheinberg,et al.  Tumor Therapy with Targeted Atomic Nanogenerators , 2001, Science.

[20]  J. Humm,et al.  Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[21]  S. Kneifel,et al.  Local Targeting of Malignant Gliomas by the Diffusible Peptidic Vector 1,4,7,10-Tetraazacyclododecane-1-Glutaric Acid-4,7,10-Triacetic Acid-Substance P , 2006, Clinical Cancer Research.

[22]  A. Perkins,et al.  Cytotoxicity of PAI2, C595 and Herceptin vectors labeled with the alpha-emitting radioisotope Bismuth-213 for ovarian cancer cell monolayers and clusters. , 2006, Cancer letters.

[23]  M. Ranson,et al.  213Bi-PAI2 conjugate selectively induces apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in a xenograft animal model , 2002, British Journal of Cancer.

[24]  A. Perkins,et al.  MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by 213Bi-C595 radioimmunoconjugate , 2004, British Journal of Cancer.

[25]  G. Goozée,et al.  In vitro testing of the leukaemia monoclonal antibody WM-53 labeled with alpha and beta emitting radioisotopes. , 2002, Leukemia research.

[26]  G. Goozée,et al.  In vitro and preclinical studies of targeted alpha therapy (TAT) for colorectal cancer , 2001, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[27]  V. Reuter,et al.  Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. , 1999, Cancer research.

[28]  C. Parker,et al.  A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer. , 2013, European urology.

[29]  B. Allen,et al.  Preclinical targeted alpha therapy for subcutaneous melanoma , 2001, Melanoma research.

[30]  R. Coleman,et al.  Clinical Experience with α-Particle–Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6 , 2007, Journal of Nuclear Medicine.

[31]  B. Oborn,et al.  Background Dose for Systemic Targeted Alpha Therapy , 2011 .

[32]  M. Brechbiel,et al.  Pharmacokinetics and toxicity of 213Bi-labeled PAI2 in preclinical targeted alpha therapy for cancer , 2007, Cancer biology & therapy.

[33]  G. Goozée,et al.  Radioimmunoconjugates for targeted alpha therapy of malignant melanoma. , 2000, Melanoma research.

[34]  A. Bj.  Can alpha-immunotherapy succeed where other systemic modalities have failed? , 1999 .

[35]  Stanley J. Goldsmith,et al.  Phase II Study of Lutetium-177–Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer , 2013, Clinical Cancer Research.

[36]  B. Oborn,et al.  Monte Carlo calculation of the maximum therapeutic gain of tumor antivascular alpha therapy. , 2012, Medical physics.

[37]  M. Ranson,et al.  Preclinical studies of targeted α therapy for breast cancer using 213Bi-labelled-plasminogen activator inhibitor type 2 , 2003, British Journal of Cancer.

[38]  J. Pagel,et al.  Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease. , 2010, Blood.

[39]  B. Allen.  Future prospects for targeted alpha therapy. , 2011, Current radiopharmaceuticals.

[40]  B. Allen,et al.  Tumour anti-vascular alpha therapy: a mechanism for the regression of solid tumours in metastatic cancer , 2007, Physics in medicine and biology.

[41]  G. Sgouros.  Radioimmunotherapy of micrometastases: sidestepping the solid-tumor hurdle. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[42]  D. Goldenberg.  Targeted therapy of cancer with radiolabeled antibodies. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[43]  J. Kerr,et al.  A histochemical study of hypertrophy and ischaemic injury of rat liver with special reference to changes in lysosomes. , 1965, The Journal of pathology and bacteriology.

[44]  J. Humm,et al.  Targeted α particle immunotherapy for myeloid leukemia , 2002 .

[45]  S Miltenyi,et al.  Immunomagnetic enrichment of disseminated epithelial tumor cells from peripheral blood by MACS. , 1998, Experimental hematology.

[46]  Yong Li,et al.  Antigenic expression of human metastatic prostate cancer cell lines for in vitro multiple-targeted alpha-therapy with 213Bi-conjugates. , 2004, International journal of radiation oncology, biology, physics.

[47]  A. Perkins,et al.  Bismuth-213 radioimmunotherapy with C595 anti–MUC1 monoclonal antibody in an ovarian cancer ascites model , 2008, Cancer biology & therapy.

[48]  G. Taucher‐Scholz,et al.  Heavy ion production of single- and double-strand breaks in plasmid DNA in aqueous solution. , 2001, Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics.

[49]  B. Allen.  Internal high linear energy transfer (LET) targeted radiotherapy for cancer , 2006, Physics in medicine and biology.

[50]  M. Brechbiel,et al.  In vivo and in vitro inhibition of pancreatic cancer growth by targeted alpha therapy using 213Bi-CHX.A”-C595 , 2005, Cancer biology & therapy.

[51]  Yong Li,et al.  Control of prostate cancer spheroid growth using 213Bi‐labeled multiple targeted α radioimmunoconjugates , 2006, The Prostate.

[52]  B. Allen.  Clinical trials of targeted alpha therapy for cancer. , 2008, Reviews on recent clinical trials.

[53]  C. Parker,et al.  Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. , 2007, The Lancet. Oncology.

[54]  R. Clarke,et al.  Orthotopic administration of (213)Bi-bevacizumab inhibits progression of PC3 xenografts in the prostate. , 2012, Immunotherapy.

[55]  B. Allen,et al.  Mutagenesis induced by targeted alpha therapy using 213Bi-cDTPA-9.2.27 in lacZ transgenic mice , 2009, Cancer biology & therapy.

[56]  Yong Li,et al.  Intralesional targeted alpha therapy for metastatic melanoma , 2005, Cancer biology & therapy.

[57]  B. Wessels,et al.  MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of α-Particle Emitters for Targeted Radionuclide Therapy* , 2010, Journal of Nuclear Medicine.

[58]  C. Milstein,et al.  Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.

[59]  L. Jacobsson,et al.  Intraperitoneal α-Particle Radioimmunotherapy of Ovarian Cancer Patients: Pharmacokinetics and Dosimetry of 211At-MX35 F(ab′)2—A Phase I Study , 2009, Journal of Nuclear Medicine.

[60]  J. Barbet,et al.  ALPHA EMITTING RADIONUCLIDES AND RADIOPHARMACEUTICALS FOR THERAPY , 2014 .

[61]  Yong Li,et al.  The cytokinesis-block micronucleus assay as a biological dosimeter for targeted alpha therapy , 2008, Physics in medicine and biology.

[62]  A. Bosserhoff,et al.  Interim analysis of toxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanoma , 2007, Cancer biology & therapy.